Mediktor fetches $3.4 mln Series A | #VentureCanvas
Iris Dorbian | PE Hub – VC (US)
Brooklyn, New York-based Mediktor, a symptom checker for pre-diagnosis, triage and decision-making support, has raised $3.4 million in Series A funding. Alta Life Sciences Spain I FCR was the lead investor.
Brooklyn, NY December 11, 2018. Mediktor announces the closure of a Series A funding round for an amount of $3.4 million. Alta Life Sciences Spain I FCR (“ALSS I FCR”) led the round. Additional investors include Castel Capital, a European-focused venture capital investor, France-based Naos, as well as other minority partners, many of whom were already “business angels” of the company.
The round provides the necessary impetus to support the commercialization of Mediktor’s Artificial Intelligence application in the North American market, to reinforce and improve the platform both technically and scientifically and to continue the company’s goal to provide the platform with greater clinical validation. To this end, Mediktor is already collaborating in an alliance with Hospital Clínic in Barcelona, making the platform the only clinically validated symptom checker in the world with a success rate of 91.3% proven in clinical trials.
Mediktor is the only clinically-validated symptom checker for pre-diagnosis, triage and decision-making support. The technology combines artificial intelligence, natural language recognition and patient data to detect symptoms and offer a listing of possible conditions, treatment recommendations and a connection with medical professionals within a health insurance network.
The platform learns from every interaction, developing an advanced intuition. Mediktor has already performed 2 million symptom evaluations in more than 200 countries globally developing an intuition comparable to a full life experience of 10 physicians.
Miguel Valls, partner of Alta Life Sciences, commented: “Mediktor technology reduces barriers to health care. Patients are empowered to make better decisions when symptoms first arise. Additionally, Mediktor enables medical professionals to organize patient demand and optimize resources to offer better medical care.”
“We are very pleased to count on the force and solidity of this great team. Alta Life Sciences from Silicon Valley and Barcelona, Castel Capital from the Netherlands and Naos with its international experience will help us to break into the US market with a strong, clinically-proven platform.” remarked Cristian Pascual, CEO and co-founder of Mediktor.
Mediktor’s entrance into the US market commenced last quarter when they opened their first US office in Brooklyn, NY. Sales outreach to health insurance providers, telemedicine platforms and other industries that benefit from Mediktor services have already begun.
Mediktor is the most advanced and accurate symptom checker for pre-diagnosis, triage and decision-making support. The technology combines artificial intelligence, natural language recognition and patient data to detect symptoms and offer a listing of possible conditions, recommendations and even connecting with medical professionals within a health insurance network.
The platform learns from every interaction, developing an advanced intuition. Mediktor has already performed 2 million symptom evaluations in more than 200 countries globally developing an intuition comparable to a full life experience of 10 physicians. The platform has undergone a clinical study with 1,015 patients achieving a success rate of 91.3% accuracy.
Founded in 2011 by Oscar García-Esquirol, doctor specialist in intensive care medicine and Cristian Pascual, industrial engineer & MBA, based in Barcelona with an office in New York. Mediktor has a multidisciplinary team of health professionals, computer scientists, experts in business development and external advisors. The company is partnering with major insurance companies and main referral hospitals across the world, including Münich RE Group, an international reinsurance company, represented in over 30 countries and concentrated on Europe and Asia.
About Alta Life Sciences
Alta Life Sciences with origins in Silicon Valley and specialized in companies in the life sciences sector in Spain and abroad is a leading multistage venture capital investment advisory firm. Alta Life Sciences targets companies at all stages of development: from seed financing through commercial growth in all areas of life sciences including biotechnology, medical devices, diagnostics, genomics and digital health.
Alta Life Sciences Spain I FCR (“ALSS I FCR”) is a bridge fund, focused in the Spanish life sciences ecosystem and connecting both sides of the Atlantic, joining the Spanish life sciences ecosystem with the Venture Capital expertise of Silicon Valley. Alta Life Sciences is the exclusive advisor to ALS Spain I FCR. Altamar Private Equity SGIIC, a leading independent firm in the management of international Private Equity and other alternative assets, is ALSS I FCR’s management company.Alta Life Sciences management team, led by Guy Nohra, is headquartered in Barcelona. The remainder of the team is formed by experienced life science professionals from the US and Spain.
About Castel Capital
Castel Capital (www.castelcapital.com) is a venture capital and private equity platform, focused on European opportunities. It is privately held and has a unique approach to working with co-investors as well as to sourcing deals. Castel Capital proactively works with all our portfolio companies and assist them with their growth path and value creation.
NAOS is a purpose-driven company with a mission, inspired by a claimed humanist utopia. A way of looking at the world, the constant desire to question and challenge the status quo in order to build a future that will never forget its ultimate aim: humankind.
Thus, 40 years ago, Jean-Noël Thorel, a pharmacist-biologist, overthrew the established understanding of the beauty industry by giving birth to a disruptive but respectful approach: ecobiology, or the art of preserving the skin ecosystem by reinforcing its natural mechanisms. Rather than over-treating the skin, it must learn how to function properly.
From this idea the brands Bioderma, Institut Esthederm and Etat Pur were born, making NAOS a major international figure in Skincare.
Today, operating in 100 countries and still as fiercely independent as ever, NAOS has the ambition to become globally known for the universal value and the originality of its approach. To achieve this goal, NAOS will be extending its scope from Skincare to Human Care (Health, Beauty, Well-being).